Sitemap
Main Menu
Top Menu
- Home
- Consultants
- Our Consultants' Biographies
- Chemist Biography
- Competative Market Intelligence, Drug Development Strategist
- CMC - Formulations Chemist
- Discovery Toxicologist (Predictive Modeling,Toxicogenomics, Cell & Molecular Biology)
- Investigative Toxicologist
- Molecular Pharmacologist – Assay Development and Drug Discovery
- Medical BioChemist / Phamacokinetic ADME / Expert Witness
- Pharmacokineticist
- Physical-Organic Chemist and Analyst
- Principal Discovery Investigator
- Project Director – Toxicology Coordinator
- Regulatory Dossier Publishing Specialist
- Strategic Regulatory Consultant
- Veterinary Pathologist and Toxicologist
- Chemist Biography
- Our Consultants' Biographies
- CROs
- Services
- Resources
- ICH Guidances
- FDA Guidances
- EPA Guidances
- Health Canada Guidances
- OECD Guidances
- Industry News
- Useful Websites
- ICH Guidances
- FDA Guidances
- FDA proposes draft guidelines intended to improve the representation of women in medical device clinical studies
- Good Laboratory Practice for Nonclinical Laboratory Studies
- Codevelopment of Two or More Unmarketed Investigational Drugs for Use in Combination
- CGMP for Phase 1 Investigational Drugs
- Investigational New Drug Applications (INDs)— Determining Whether Human Research Studies Can Be Conducted Without an IND
- FDA Residual Drug in Transdermal and Related Drug Delivery Systems
- FDA Issues Assessments of the 510(k) Program and Use of Science in Decision-Making
- Addendum to ICH S6: Preclinical Safety Evaluation of Biotechnology-Derived
- Animal Models - Essential Elements to Address Efficacy Under the Animal Rule
- Nonclinical Safety Evaluation of Reformulated Drug Products and Products Intended for Administration
- Nonclinical Safety Evaluation of Pediatric Drug Products
- Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients
- Photosafety Testing
- Recommended Approaches to Integration of Genetic Toxicology Study Result
- Redbook 2000
- Reference Guide for the Nonclinical Toxicity Studies of Antiviral Drugs Indicated for the Treatment
- S7B- SP QT Interval Prolongation by Human Pharmaceuticals
- Safety Testing of Drug Metabolites
- Single Dose Acute Toxicity Testing for Pharmaceuticals
- Nonclinical Safety Evaluation of Drug or Biologic Combinations
- Nonclinical Pharmacology/Toxicology Development of Topical Drugs Intended to Prevent the Transmissio
- Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic Radiopharmaceuticals
- Carcinogenicity Study Protocol Submissions:
- Content and Format of INDs for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic,
- Content and Format of Investigational New Drug Apps (INDs) for Phase 1 Drugs
- Developing Medical Imaging Drug and Biological Products, Part 1: Conducting Safety Assessments
- Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healt
- Exploratory IND Studies
- Format and Content of the Nonclinical Pharmacology/Toxicology Section of an Application
- Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches
- Immunotoxicology Evaluation of Investigational New Drugs
- Integration of Study Results to Assess Concerns about Human Reproductive and Developmental Toxicitie
- Statistical Aspects of the Design, Analysis, and Interpretation of Chronic Rodent Carcinogenicity Studies of Pharmaceuticals
- EPA Guidances
- Health Canada Guidances
- OECD Guidances
- OECD Principles of Good Laboratory Practice
- Requesting and Carrying out Inspections and Study Audits in another country
- The Role and Responsibility of the Sponsor in the Application of the Principles of GLP
- The Application of the Principles of GLP to Computerised Systems
- Guidance for the Preparation of GLP Inspection Reports
- The Role and Responsibilities of the Study Director in GLP Studies
- The Application of the GLP Principles to Short Term Studies
- The Application of the GLP Principles to Field Studies
- Compliance of Laboratory Suppliers with GLP Principles
- Quality Assurance and GLP
- Revised Guidance for the Conduct of Laboratory Inspections and Study Audit
- OECD Series on Principles of Good Laboratory Practice and Compliance Monitoring
- The Application of the OECD Principles of GLP to the Organisation and Management of Multi-site Studies
- OECD
- Tips
- Contact Us
Services Provided by PharmaFacts Consultants
